Paediatric HIV
Saving children’s lives by developing new treatments to meet their needs
Paediatric HIV
Saving children’s lives by developing new treatments to meet their needs
We developed an easy-to-administer, strawberry-flavoured combination of four antiretroviral medicines to meet the needs of the youngest children, who are at the highest risk of dying without treatment. With regulatory review underway, our partnerships are working to ensure quick treatment roll-out for thousands of children in need.
The needs of children with HIV have long been neglected. While R&D efforts have succeeded in developing life-saving diagnosis and treatment innovations for adults, innovation for children lags far behind.
Until recently, the only treatments available for babies and kids were bitter-tasting, difficult to dose, and required refrigeration – making them unsuitable for children and their caregivers. Thankfully, new paediatric formulations are finally becoming available after decades of poor options. Our work is a key part of this revolution in paediatric HIV diagnosis and treatment.
‘The initial treatment was difficult to administer because of their bitter taste. Many times, Emmanuel would spit the medication instead of swallowing.’
What we have achieved
Our research is helping countries replace older, difficult–to–use, and sometimes ineffective formulations and scale up new, optimum treatments for young children.
What we are doing for children living with HIV
In order to help end the neglect of babies and young children with HIV, we have developed an easy-to-administer, strawberry-flavoured ‘4-in-1’ treatment called Quadrimune, together with the Indian company Cipla. But our engagement goes well beyond drug development alone. Through a series of partnerships, we are working to ensure improved treatments for kids are rolled out where they are needed most.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
